Trial overview

IMCOVAS

Assessment of the immunogenicity and safety of marketed vaccines for COVID-19 after regular schedule and adapted vaccine schedules and routes: BNT162b2 (Comirnaty®; Pfizer-BioNTech), mRNA-1273 vaccine (COVID-19 vaccine Moderna®; Moderna) and COVID-19 vaccine (ChAdOx1-S [recombinant])(Vaxzevria®, AstraZeneca)
shutterstock_1643947495

About the clinical trial

The IMCOVAS study was a clinical trial investigating eight different vaccination strategies with three COVID-19 vaccines for efficacy and safety:

  • Comirnaty® (Pfizer-BioNTech)

  • Spikevax® (Moderna)

  • Vaxzevria® (AstraZeneca)

The study was sponsored by our academic partner University of Antwerp and funded by the Federal Knowledge Centre for Health Care (KCE).

The study involved 168 healthy people aged between 18 and 55 years. The participants were not allowed to have already experienced COVID-19 infection, nor to have received a COVID-19 vaccine.

The study consisted of seven visits to our study centre and lasted from June 2021 to July 2022.

For more scientific background on the study, please visit the publicly accessible database in which the study is registered.

Team

Questions?

Contact us at studies@itg.be.

Registration closed

We are no longer accepting participants for this trial, but there may be other trials ongoing for which you can register. An overview can be found here. Would you like to stay informed about upcoming trials? Be sure to sign up for our mailing list.

Sign up

Share this trial on